Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Cancer Science

Volumn 101, Issue 9, 2010, Pages 2059-2064

  Ohmachi, Ken ^a   Ando, Kiyoshi ^a   Ogura, Michinori ^b   Uchida, Toshiki ^b   Itoh, Kuniaki ^c   Kubota, Nobuko ^c   Ishizawa, Kenichi ^d   Yamamoto, Joji ^d   Watanabe, Takashi ^e   Uike, Naokuni ^f   Choi, Ilseung ^f   Terui, Yasuhito ^g   Usuki, Kensuke ^h   Nagai, Hirokazu ⁱ   Uoshima, Nobuhiko ^j   Tobinai, Kensei ^e  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h Kanto Teishin Hospital   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^j MATSUSHITA MEMORIAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE;

ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HISTOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL PHARYNGITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; PNEUMONIA; RECURRENCE; TREATMENT OUTCOME; VOMITING;

EID: 77955944557     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01635.x     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002, updated as of October 27, 2009. CA Cancer J Clin 2009, 55:74-108.
2. Cancer Facts & Figures 2009 2009, American Cancer Society, Atlanta, GA, American Cancer Society
3. Cancer Statistics in Japan 2009, Foundation for Promotion of Cancer Research, Tokyo, Foundation for Promotion of Cancer Research
4. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
5. Rosenberg SA. Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J Clin Oncol 1985, 3:299-310.
6. Fisher RI, Leblanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447-52.
7. Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-32.
8. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711-6.
9. Czuczman MS, Grillo-Lopez AJ, White CA. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-76.
10. Yatabe Y, Suzuki R, Tobinai K. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000, 95:2253-61.
11. Teodorovic I, Pittaluga S, Kluin-Nelemans JC. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819-26.
12. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995, 85:1075-82.
13. Aoki R, Karube K, Sugita Y. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int 2008, 58:174-82.
14. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005, 17:425-31.
15. Leoni LM, Bailey B, Reifert J. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14:309-17.
16. Hirschberg E, Gellhorn A, Gump WS. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl)amino-methyl]benzimidazole, and of other 2-chloroethyl compounds. Cancer Res 1957, 17:904-10.
17. Schwanen C, Hecker T, Hubinger G. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002, 16:2096-105.
18. Chow KU, Boehrer S, Geduldig K. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001, 86:485-93.
19. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996, 7:415-21.
20. Friedberg JW, Cohen P, Chen L. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26:204-10.
21. Kahl BS, Bartlett NL, Leonard JP. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010, 116:106-14.
22. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues 2001, 3rd edn, Geneva, World Health Organization
23. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-55.
24. Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999, 17:1244.
25. Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-86.
26. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 2006, http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf, CTCAE, Bethesda, MD, National Cancer Institute, US National Institutes of Health, Available from URL:
27. Solal-Celigny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-65.
28. Robinson KS, Williams ME, Van der Jagt RH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-9.